capecitabine has been researched along with B16 Melanoma in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Huang, WD; Shen, SY; Zheng, MF | 1 |
1 other study(ies) available for capecitabine and B16 Melanoma
Article | Year |
---|---|
DCA increases the antitumor effects of capecitabine in a mouse B16 melanoma allograft and a human non-small cell lung cancer A549 xenograft.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Dichloroacetic Acid; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Humans; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Proteins; Prodrugs; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Random Allocation; Thymidine Phosphorylase; Xenograft Model Antitumor Assays | 2013 |